Patents by Inventor Thangavel Kuberasampath
Thangavel Kuberasampath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6194376Abstract: The invention provides methods for alleviating immune cell mediated inflammatory responses to injury to mammalian tissue. The present methods make use of osteogenic protein 1(OP-1), which is appreciated herein as tissue morphogen, i.e., a substance competent to induce tissue-specific morphogenesis of mammalian body tissues in addition to bone and/or cartilage. Alternatively, the present methods make use of other naturally-occurring or biosynthetic proteins sharing a defined structural and functional relationship with OP-1 and thus appreciated herein also to be tissue morphogens. The invention is particularly adapted to alleviating tissue damage associated with ischemia-reperfusion injury or hyperoxia injury in mammals, including humans.Type: GrantFiled: March 30, 1995Date of Patent: February 27, 2001Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger, Charles M. Cohen
-
Patent number: 6153583Abstract: Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.Type: GrantFiled: December 23, 1998Date of Patent: November 28, 2000Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 6093547Abstract: Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.Type: GrantFiled: June 2, 1995Date of Patent: July 25, 2000Assignee: Creative Biomolecules, Inc.Inventors: Donald F. Jin, Hermann Oppermann, Thangavel Kuberasampath, John E. Smart
-
Patent number: 6090776Abstract: The present invention is directed to methods and compositions for enhancing viability of organs and living tissues to be transplanted in a mammal. The methods and compositions provide a therapeutically effective concentration of a morphogen or morphogen-stimulating agent to the tissue or organ to be transplanted, sufficient to substantially protect the tissue or organ from tissue damage.Type: GrantFiled: June 7, 1995Date of Patent: July 18, 2000Assignee: Creative Bio Molecules, Inc.Inventors: Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger, Charles M. Cohen, John E. Smart
-
Patent number: 6077988Abstract: Disclosed is an osteogenic device capable of inducing the formation of endochondral bone in a shape conforming substantially to the shape of the device when implanted in a mammalian host. The device includes an osteogenic protein dispersed within a porous matrix comprising a polymer of collagen and glycosaminoglycan cross-linked to an M.sub.c value of about 800 to about 60,000. Also disclosed are a method of inducing mammalian bone growth, and a method of inducing conductive bone growth from viable mammalian bone.Type: GrantFiled: May 18, 1995Date of Patent: June 20, 2000Assignee: Stryker Biotech CorporationInventors: Thangavel Kuberasampath, Lawrence Berlowitz Tarrant
-
Patent number: 6077823Abstract: The present invention is directed to methods and compositions for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The methods and compositions include administering a therapeutically effective concentration of a morphogen or morphogen-stimulating agent sufficient to alleviate immune cell-mediated tissue destruction.Type: GrantFiled: May 22, 1995Date of Patent: June 20, 2000Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger, Charles M. Cohen, John E. Smart
-
Patent number: 6071708Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.Type: GrantFiled: July 8, 1997Date of Patent: June 6, 2000Assignee: Stryker BiotechInventors: William K. Jones, Ronald F. Tucker, David C. Rueger, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath
-
Patent number: 6022853Abstract: Disclosed are methods and compositions useful in dietary applications and capable of enhancing tissue morphogenesis, including tissue development and viability in a mammal, particularly a human. The methods and compositions include a morphogen which, when provided to an individual as a food formulation or supplement, is capable of enhancing tissue development and viability in the individual.Type: GrantFiled: July 20, 1994Date of Patent: February 8, 2000Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, Charles M. Cohen, David C. Rueger, Hermann Oppermann, Roy H. L. Pang
-
Patent number: 5994131Abstract: Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, incubating a candidate compound with the culture for a time sufficient to allow the compound to affect the production of the morphogenic protein, and then assaying the culture again to detect a change in the level of morphogenic protein production.Type: GrantFiled: August 15, 1997Date of Patent: November 30, 1999Assignee: Creative BioMolecules, Inc.Inventors: John E. Smart, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5972884Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: October 26, 1999Assignee: Creative BioMolecules, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang
-
Patent number: 5958441Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: May 24, 1995Date of Patent: September 28, 1999Assignee: Stryker Biotech CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 5863758Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: May 23, 1994Date of Patent: January 26, 1999Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 5861479Abstract: Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.Type: GrantFiled: June 2, 1995Date of Patent: January 19, 1999Assignee: Creative BioMolecules, Inc.Inventors: Donald F. Jin, Hermann Oppermann, Thangavel Kuberasampath, John E. Smart
-
Patent number: 5854071Abstract: Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.Type: GrantFiled: July 28, 1997Date of Patent: December 29, 1998Assignee: Creative BioMolecules, Inc.Inventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5849686Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining liver function in a mammal, including methods, compositions and devices for regenerating lost or damaged hepatic tisse, enhancing viability and integration of hepatic tissue and organ transplants, and correcting liver function deficiencies. The methods, compositions and devices on this invention all provide a therapeutically effective morphogen concentration to the hepatic cells to be treated.Type: GrantFiled: May 22, 1995Date of Patent: December 15, 1998Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5840325Abstract: Disclosed are osteogenic devices comprising a matrix containing substantially pure mammalian osteogenic protein and methods of inducing endochondral bone growth in mammals. A partial amino acid sequence, amino acid composition, solubility properties, and various other data characterizing osteogenic protein are also disclosed, as well as a nucleic acid sequences encoding a consensus osteogenic protein.Type: GrantFiled: February 26, 1996Date of Patent: November 24, 1998Assignee: Stryker CorporationInventors: Thangavel Kuberasampath, David C. Rueger
-
Patent number: 5834179Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.Type: GrantFiled: June 2, 1995Date of Patent: November 10, 1998Assignee: Creative BioMoleculesInventors: William K. Jones, Ronald F. Tucker, David C. Rueger, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath
-
Patent number: 5831050Abstract: Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.Type: GrantFiled: December 16, 1994Date of Patent: November 3, 1998Assignee: Creative BioMolecules, Inc.Inventors: Donald F. Jin, Hermann Oppermann, Thangavel Kuberasampath, John E. Smart
-
Patent number: 5814604Abstract: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.Type: GrantFiled: April 4, 1995Date of Patent: September 29, 1998Assignee: Stryker CorporationInventors: Hermann Oppermann, Thangavel Kuberasampath, David C. Rueger, Engin Ozkaynak
-
Patent number: 5750651Abstract: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.Type: GrantFiled: November 1, 1993Date of Patent: May 12, 1998Assignee: Stryker CorporationInventors: Hermann Oppermann, Thangavel Kuberasampath, David C. Rueger, Engin Ozkaynak